Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy.

ABSTRACT: Oncolytic viruses (OVs) are an emerging class of therapeutics which combine multiple mechanisms of action, including direct cancer cell-killing, immunotherapy and gene therapy. A growing number of clinical trials have indicated that OVs have an excellent safety profile and provide some degree of efficacy, but to date only a single OV drug, HSV-1 talimogene laherparepvec (T-Vec), has achieved marketing approval in the US and Europe. An important issue to consider in order to accelerate the clinical advancement of OV agents is the development of an effective delivery system. Currently, the most commonly employed OV delivery route is intratumoral; however, to target metastatic diseases and tumors that cannot be directly accessed, it is of great interest to develop effective approaches for the

SUBMITTER: Reale A 

PROVIDER: S-EPMC8709025 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature